INT-767

• Description:

  INT-767 is a dual farnesoid X receptor (FXR) /TGR5 agonist with mean EC50s of 30 and 630 nM, respectively[1][2].

• UNSPSC:

  12352100

• Target:

  Autophagy; FXR; G protein-coupled Bile Acid Receptor 1

• Type:

  Reference compound

• Related Pathways:

  Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/INT-767.html

• Purity:

  99.81

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  C[C@H](CCOS(=O)(O[Na])=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C

• Molecular Formula:

  C25H43NaO6S

• Molecular Weight:

  494.66

• References & Citations:

  [1]Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mousecholangiopathy model by promoting biliary HCO3- output. Hepatology. 2011 Oct;54 (4) :1303-1312.|[2]Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor andTGR5 agonist. Mol Pharmacol. 2010 Oct;78 (4) :617-630.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1000403-03-1